Changes in calculated coronary heart disease risk using proactive multifactorial intervention versus continued usual care in Latin-American and non-Latin-American patients enrolled in the CRUCIAL trial

Current Medical Research and Opinion

Volumn 28, Issue 10, 2012, Pages 1667-1676

  Pavia, Abel ^a   Zamorano, José ^b   Sutradhar, Santosh ^c   Yunis, Carla ^c  

^a Hospital General de México   (Mexico)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c PFIZER INC   (United States)

Author keywords

Amlodipine; Atorvastatin; Cardiovascular Risk; Dyslipidemia; Hypertension; Latin America

Indexed keywords

AMLODIPINE PLUS ATORVASTATIN; CHOLESTEROL;

ADULT; AGED; ARTICLE; CALCULATION; CARDIAC PATIENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLUSTER ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HUMAN; HYPERTENSION; INTERVENTION STUDY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PILL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; WESTERN HEMISPHERE;

ADULT; AGED; AMLODIPINE; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CORONARY DISEASE; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PYRROLES; RISK FACTORS;

EID: 84867866126     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.725391     Document Type: Article

References (29)

1. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52 (Pubitemid 39208455)
2. Albala C, Vio F, Yanez M. Epidemiological transition in Latin America: a comparison of four countries. Revista medica de Chile 1997;125:719-27 (Pubitemid 127542246)
3. Lanas F, Avezum A, Bautista LE, et al. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. Circulation 2007; 115:1067-74 (Pubitemid 46673168)
4. Rubinstein A, Colantonio L, Bardach A, et al. Estimate of the cardiovascular disease burden attributable to modifiable risk factors in Argentina. Pan Am J Publ Health 2010;27:237-45
5. Hernandez-Hernandez R, Silva H, Velasco M, et al. Hypertension in seven Latin American cities: the Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study. J Hypertension 2010;28:24-34
6. Silva H, Hernandez-Hernandez R, Vinueza R, et al. Cardiovascular risk awareness, treatment, and control in urban Latin America. Am J Therapeut 2010; 17:159-66
7. Vinueza R, Boissonnet CP, Acevedo M, et al. Dyslipidemia in seven Latin American cities: CARMELA study. Prev Med 2010;50:106-11
8. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension 2007;25:1105-87 (Pubitemid 46924065)
9. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106: 3143-421
10. Avezum A, Braga J, Santos I, et al. Cardiovascular disease in South America: current status and opportunities for prevention. Heart (British Cardiac Society) 2009;95:1475-82
11. UN General Assembly. Political declaration on noncommunicable disease prevention and control 19-20 September 2011. Available at: http://www.who.int/ nmh/events/un-ncd-summit2011/en/[Last accessed 7 March 2011]
12. Zamorano J, Erdine S, Lopez AP, et al. Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. Postgrad Med 2010;122:7-15
13. Zamorano J, Erdine S, Pavia A, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin 2011;27:821-33
14. Blank R, LaSalle J, Reeves R, et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). J Clin Hypertension (Greenwich, Conn) 2005; 7:264-73
15. Erdine S, Ro YM, Tse HF, et al. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J Human Hypertension 2009; 23:196-210
16. Flack JM, Victor R, Watson K, et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clinic Proceedings 2008;83:35-45
17. Hobbs F, Gensini G, Feldman R, et al. An international open-label program to assess the efficacy of single-pill amlodipine/atorvastatin in attaining recommended BP and lipid levels: The JEWEL Programme. Eur J Cardiovasc Prev Rehabil 2009;16:472-80
18. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
19. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58 (Pubitemid 36398384)
20. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120: 713-19 (Pubitemid 47176510)
21. Chapman RH, Yeaw J, Roberts CS. Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. BMC Cardiovasc Disord 2010; 10:29
22. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119:3028-35
23. Simons LA, Ortiz M, Calcino G. Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006-2010. Med J Aust 2011;195:134-7
24. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47 (Pubitemid 28213628)
25. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23 (Pubitemid 40138015)
26. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52 (Pubitemid 37553153)
27. Touboul PJ, Hernandez-Hernandez R, Kucukoglu S, et al. Carotid artery intima media thickness, plaque and Framingham cardiovascular score in Asia, Africa/Middle East and Latin America: the PARC-AALA study. Int J Cardiovasc Imag 2007;23:557-67
28. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147-52 (Pubitemid 40720739)
29. Medical Research Council. MRC cluster randomized trials: methodological and ethical considerations. London: MRC, 2002